HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bennink, R. J. Articles by Sloof, G. W. Search for Related Content PubMed PubMed Citation Articles by Bennink, R. J. Articles by Sloof, G. W.

In Vivo Prediction of Response to Antiestrogen Treatment in Estrogen Receptor-Positive Breast Cancer

¹ Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
² Department of Radiotherapy, Academic Medical Center, Amsterdam, The Netherlands
³ Amersham Health and Eindhoven University of Technology, Eindhoven, The Netherlands
⁴ Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands

In metastatic breast cancer, the estrogen receptor (ER) is a well-known prognostic factor predictive of response to hormonal treatment in most, but not all, patients. Recently, a receptor-specific radioligand for in vivo imaging of the ER in breast cancer patients was developed: ¹²³I-labeled cis-11ß-methoxy-17-iodovinyl-estradiol (Z-¹²³I-MIVE). It showed high sensitivity and specificity for the in vivo detection of ER-positive breast cancer. The aim of this study was to determine whether Z-¹²³I-MIVE scintigraphy is able to predict response or resistance to antiestrogen therapy in patients with metastatic ER-positive breast carcinoma. Methods: Twenty-three patients with first metastases of their breast cancer and positive Z-¹²³I-MIVE scintigraphy were included and treated with tamoxifen, 40 mg/d. Scintigraphy was repeated, on average, 4 wk later. The results of these scintigraphies were compared with the clinical outcome. Results: On baseline scintigraphy, 21 of 23 patients had clear uptake and 2 of 23 patients had faint uptake of Z-¹²³I-MIVE. After initiation of antiestrogen treatment, 17 of 21 patients with clear uptake on baseline scintigraphy showed complete blockade of ER activity on the Z-¹²³I-MIVE scintigraphy. Four of 21 patients showed mixed or no ER blockade. All patients with faint baseline uptake or mixed or no ER blockade after tamoxifen showed progressive disease despite antiestrogen treatment. Patients with clear baseline uptake and complete ER blockade after tamoxifen had a significantly longer progression-free interval (mean ± SEM, 14.4 ± 1.6 vs. 1.8 ± 0.8 mo; P < 0.01). Conclusion: Z-¹²³I-MIVE scintigraphy seems to be a useful tool to predict response or resistance to antiestrogen treatment in ER-positive metastatic breast cancer patients and to depict nonresponders before the clinical manifestation of progression.

Key Words: breast cancer • estrogen receptor • radionuclide imaging • tamoxifen

This article has been cited by other articles:

				T. K. Nayak, H. J. Hathaway, C. Ramesh, J. B. Arterburn, D. Dai, L. A. Sklar, J. P. Norenberg, and E. R. Prossnitz Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers J. Nucl. Med., June 1, 2008; 49(6): 978 - 986. [Abstract] [Full Text] [PDF]

				S Reddy, M Kurli, L B Tena, and P T Finger PET/CT imaging: detection of choroidal melanoma Br J Ophthalmol, October 1, 2005; 89(10): 1265 - 1269. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]